



SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Bplex, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.
E-mail : compliance@sudarshanpharma.com, Website : www.sudarshanpharma.com
Board Line : +91-22-42221111 / 43331111/42221116 (100 line) CIN: L51496MH2008PLC184997

SPI/CS/SE/2025-2026/69

Date: 30th January 2026

To,
The Listing Department
BSE Limited
Pheroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

BSE Scrip Code: 543828
BSE Trading Symbol: SUDARSHAN
ISIN: INE00TV01023

Sub: Newspaper Advertisement – Unaudited Financial Results for the quarter and nine months ended 31st December 2025

Dear Sir / Madam,

Please find enclosed herewith the newspaper advertisement for the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended 31st December 2025, published in the following newspapers:

1. Mumbai Lakshdeep and
2. Financial Express.

Request you to take the same on your record.

For, Sudarshan Pharma Industries Limited

Nirav Shah
Company Secretary & Compliance Officer

Encl: As above



AUTOMOTIVE STAMPINGS AND ASSEMBLIES LIMITED

Regd Office: TACO House, Plot No. 20/B FPN085, V. G. Damle Path, Off Law College Road, Erandwane, Pune: 411004 | Email: cs@autostampings.com | CIN: L28932PN1990PLC016314

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025

The Board of Directors of the Company at their Meeting held on January 28, 2026 approved the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2025.

The Results, along with Limited Review Report have been published on the Company's website at www.autostampings.com and can be accessed by scanning the following QR Code.



For AUTOMOTIVE STAMPINGS AND ASSEMBLIES LIMITED

Arvind Goel

Chairman

DIN:02300813

By order of the Board

Place : Pune
Date : January 28, 2026

For AUTOMOTIVE STAMPINGS AND ASSEMBLIES LIMITED

Arvind Goel

Chairman

DIN:02300813

By order of the Board

Note : The above information is in accordance with Regulation 33 read with 47(1) of the SEBI (LODR) Regulations, 2015

EIKO LIFESCIENCES

FEEL THE CHEMISTRY

(CIN: L65923MH1977PLC258134)

Regd off: 604, Centrum, Opp. TMC Office, Near Satkar Grand Hotel, Wagholi Estate, Thane West MH 400604
Email: investor.relations@eikolifesciences.com, Phone No.: +91903268855; website: www.eikolifesciences.com

EXTRACT OF UNAUDITED STADNALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31-12-2025

Sr. No.	Particulars	Standalone			Consolidated			(In Lakhs except EPS)
		Quarter Ended	Nine Months Ended	Year ended	Quarter Ended	Nine Months Ended	Year ended	
1	Total Income from Operations	1,013.61	3,765.21	7,015.54	2,769.82	8,589.79	3,351.56	1,230.07
2	Net profit / (Loss) for the period (before tax, before Exceptional items and before share of profit of Associates)	124.36	106.90	38.08	321.97	112.23	197.69	167.13
3	Net profit / (Loss) before tax (after Exceptional items and before share of profit of associates)	124.39	106.90	38.08	321.97	112.23	231.82	167.13
4	Net profit / (Loss) (before tax (after Exceptional items and after share of profit of associates)	124.39	106.90	38.08	321.97	112.23	231.82	190.22
5	Net profit / (Loss) after tax (after Exceptional items and after share of profit of associates)	94.74	81.78	26.49	245.72	83.96	174.08	142.55
6	Equity Comprehensive Income for the period (Comprising Profit/(Loss) for the period (before tax), share of profit of Associates and Other Comprehensive Income (after tax))	94.74	81.78	26.49	245.72	83.96	174.08	142.55
7	Paid up equity share Capital	1,372.09	1,372.09	1,287.28	1,372.09	1,378.27	1,372.09	1,287.28
8	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance sheet of the previous year	-	-	-	-	4,266.10	-	-
9	Basic Earning Per Share (Not Annualised) (EPS in ₹)	0.69	0.60	0.16	1.79	0.43	1.34	0.88
10	Diluted Earning Per Share (Not Annualised) (EPS in ₹)	0.69	0.60	0.16	1.79	0.43	1.34	0.88

1 The above Unaudited Standalone and Consolidated Financial results for the quarter and nine months ended 31st December, 2025 was reviewed by the audit committee of the board on 29th January, 2026 and thereafter approved by the board of directors of the company at their meeting held on 29th January, 2026. The Limited Audit Report issued by Statutory Auditor has no qualification / modification.
2 These Financial Results have been prepared in accordance with Indian Accounting Standards ("IAS") notified under Section 133 of the Companies Act 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended)
3 The above is an extract of the details format of quarter and nine months ended results filed with the stock exchange under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. The full format of the quarter and nine months ended 31st December, 2025 Financial Results are available on stock exchange website at www.bseindia.com and also on the company's website i.e., www.eikolifesciences.com
4 The Company's Consolidated Financial Results include financial results of a) Eko Scientific Solutions LLP - 100% Direct Subsidiary
b) EkoWays Logistics Private Limited - 100% subsidiary
c) Relax Pharmaceuticals Private Limited- Associate Company.



For Eiko Lifesciences Limited
Sd/-
Clinton Doshi
Company Secretary & Compliance Officer
A32190

Date: 29-01-2026

Place: Thane

UPDATE (MSETCL)

MSETCL celebrates 77th Republic Day with patriotic fervor at Prakashganga



The Maharashtra State Electricity Transmission Company Ltd (MSETCL) celebrated the 77th Republic Day with great enthusiasm at its headquarters, Prakashganga, in Mumbai. Similar celebrations and programmes were also organised across

CORPORATE BRIEFS



UPDATE (WR)

Gm/wr Unfurled The National Flag On The Occasion Of 77th Republic Day

The 77th Republic Day of our nation was celebrated over Western Railway by



ICICI Bank

Regd. Office: ICICI Bank Limited, ICICI Bank Tower, Near Chakki Circle, Old Pedro Road, Vaddodara, Gujarat, Pin- 390 007
Corporate Office: ICICI Bank Towers, Bandra - Kurla Complex, Bandra (E), Mumbai - 400 051
Regional Office: ICICI Bank Limited, Technopolis Building, 4th Floor, Sector - V, Salt Lake City, Kolkata - 700098

PUBLIC NOTICE E-AUCTION OF ASSIGNMENT OF FINANCIAL ASSET

In terms of the policy of ICICI Bank Limited ("ICICI Bank") on Sale of Financial Assets and in line with the regulatory guidelines, ICICI Bank hereby invites Expression of Interest ("EOI") from Interested ARCs/Banks/NFCs/FIs for purchase of Non-Performing Asset ("Financial Asset") on the terms and conditions indicated herein. It is hereby clarified that confirmation of the name of successful bidder will be subject to final approval by the competent authority of ICICI Bank.

Reserve Price (RP)	Incremental Bid on RP	Terms of Sale
₹ 75.5 million	1.0 million	100% in Cash basis

Schedule for E-Auction:

Sr. No.	Activity	Date & Time
1.	Submission of Expression of Interest ("EOI")	February 06, 2026, latest by 05:00 PM
2.	Execution of Non-Disclosure Agreement ("NDA") (if not already executed with ICICI Bank)	February 07, 2026, latest by 05:00 PM
3.	Release of Offer Document along with Preliminary Information Memorandum ("PIM")	February 07, 2026
4.	Access to data room for due diligence	February 08, 2026 to February 23, 2026 (between 10:00 A.M. to 05:00 P.M.)
5.	Submission of Bid Form	February 24, 2026, latest by 05:00 PM
6.	Process of e-bidding	February 25, 2026, from 11:00 A.M. to 12:00 P.M. with auto extension of five minutes till sale is completed

TERMS & CONDITIONS

The sole Financial Asset is on "As is Where is Basis", "As is What is Basis", "Whatever There is Basis" and "Without Previous Basis".

The e-bidding process will be conducted through M/s e-Procurement Technologies Ltd (Auctoniger) on the website of auction agency, <https://icicibank-auctoniger.net> on date and time as above. The e-bidding process shall be subject to terms & conditions contained in the offer document which will be made available to Parties post execution of NDA.

For any further clarifications with regard to data room, terms and conditions of the auction or submission of EOIs, Bids, kindly contact Mr. Abhishek Verma, mobile: +91 7004972854, email: verma.ab@icicibank.com. EOIs/Bids to be submitted by 05:00 PM of the day prior to the auction date.

ICICI Bank will not be responsible for any loss or damage arising out of non-receipt of EOI for the reasons beyond the control of the Bank. Interested Parties are expected to take all necessary steps to find out the status of communication sent to them by ICICI Bank to ensure their participation in the auction process.

This notice and contents hereof are subject to any prevailing laws, rules and regulations of India.

Date : January 30, 2026

Authorised Officer
ICICI Bank Limited

SUDARSHAN PHARMA INDUSTRIES LIMITED

Registered Office: 301, 3rd Floor, Aurora Biprox, Above Kalyan Jewellers, S. V. Road, Borivali (West), Mumbai - 400092
Board Room: +91 - 22 - 42221111, E-mail: compliance@sudarshanpharma.com
Website : www.sudarshanpharma.com

EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2025

(Figures are Rupees in Lakhs unless specified)

Sr. no.	Particulars	Quarter Ended			Nine Months Ended			Year Ended (Audited)
		31st Dec, 2025	30th Sept, 2025	31st Dec, 2024	31st Dec, 2024	31st Dec, 2024	31st Dec, 2024	
1.	Total Income from Operations	15,860.56	16,956.70	11,565.23	48,213.52	34,344.13	50,523.52	
2.	Net Profit / (Loss) for the period (before tax, exceptional and/or extraordinary items)	519.04	422.80	385.10	1,483.53	1,129.46	2,283.40	
3.	Net Profit / (Loss) for the period before tax (After exceptional and/or extraordinary items)	519.04	422.80	385.10	1,483.53	1,129.46	2,283.40	
4.	Net Profit / (Loss) for the period after tax (After exceptional and/or extraordinary items)	435.71	418.34	288.20	1,257.70	755.39	1,496.76	
5.	Total Comprehensive Income for the Period	435.71	418.34	288.20	1,257.70	755.39	1,496.76	
6.	Equity Share Capital (Face Value of Rupee 1/- per share)	2,406.59	2,405.59	2,405.59	1,195.25	752.64	1,492.95	
7.	Reserve Excluding Revaluation Reserve	8	8	8	2,405.59	2,405.59	2,405.59	
(a) Basic		0.16	0.16	0.12	0.50	0.31	0.62	
(b) Diluted		0.16	0.16	0.12	0.49	0.31	0.62	

Financial Information on Standalone basis is as below:

Sr. no.	Particulars	Quarter Ended			Nine Months Ended			Year Ended (Audited)
		31st Dec, 2025	30th Sept, 2025	31st Dec, 2024	31st Dec, 2024	31st Dec, 2024	31st Dec, 2024	
1.	Revenue from Operations	15,837.13	18,700.63	11,558.23	46,766.87	34,092.53	50,249.34	
2.	Profit before tax	430.54	440.03	275.92	1,243.59	896.47	1,402.16	
3.	Profit after tax	430.54	440.03	275.92	1,243.59	896.47	1,402.16	

Notes :

1. The Above extract of the detailed format of Quarterly Results filed with the Stock Exchange Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. The Full format of Quarterly Results are available on the website of the Stock Exchange www.bseindia.com and the Company's website www.sudarshanpharma.com.

2. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 26th January, 2026.

For, Sudarshan Pharma Industries Limited

Sd/-

Sachin Mehta

Joint Managing Director & Chief Financial Officer

DIN: 02211178

UPDATE (MSETCL)

MSETCL celebrates 77th Republic Day with patriotic fervor at Prakashganga



The Maharashtra State Electricity Transmission Company Ltd (MSETCL) celebrated the 77th Republic Day with great enthusiasm at its headquarters, Prakashganga, in Mumbai. Similar celebrations and programmes were also organised across

the nation.